Use of HER2, BRAF, and Immunotherapy in Clinical Practice
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains how to integrate HER2, BRAF, and immunotherapy into clinical practice. This was recorded at the 2017 Great Debates and Updates in GI Malignancie...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, Targets
In this presentation from the 14th Annual Best of San Antonio - Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2...
Author: imedex
Added: 04/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Phase Ib Trial Evaluating T-DMI with Neratinib in Women with Metastatic HER2+ Breast Cancer
Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic...
Author: aacr2017
Added: 04/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2017 Category: Cancer & Oncology Source Type: podcasts
Breast Cancer 2016: The Lancet: December 6, 2016
Sibylle Loibl discusses recent advances in the treatment of oestrogen receptor positive, HER2-positive, and triple-negative breast cancers. (Source: Listen to The Lancet)
Source: Listen to The Lancet - December 7, 2016 Category: General Medicine Authors: The Lancet Source Type: podcasts
Bonanza of New Options for HR+/HER2- Breast Cancer
Patients with advanced HR-positive/HER2-negative breast cancer may benefit from practice-changing treatment options, as reported by Dr Javier Cort é s from ESMO 2016. (Source: Medscape Oncology)
Source: Medscape Oncology - October 19, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Targeting HER 2 and angiogenesis in gastric cancer: What is the impact?
In this presentation from the ESMO 18th World Congress on Gastrointestinal Cancer, Dr. Andrs Cervantes discusses the impact of targeting HER2 and angiogenesis in gastric cancer.
Author: imedex
Added: 08/19/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 19, 2016 Category: Cancer & Oncology Source Type: podcasts
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Erika Hamilton of Sarah Cannon Research Institute, Nashville, TN talks about a Phase I trial of ONT-380 in combination with capecitabine and T-DM1 (trastuzumab emtansine), in patients with HER2+ metas...
Author: VJOncology
Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts
Kimberly L. Blackwell, MD - Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - August 10, 2016 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities
In this presentation from the "17th Annual Congress: Perspectives in Lung Cancer", Dr. Lucio Crinò discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities av...
Author: imedex
Added: 05/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 22, 2016 Category: Cancer & Oncology Source Type: podcasts
HER2 Mutation Positive NSCLC
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
http://cancergrace.org/lung......
Author: cancergrace
Added: 02/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2016 Category: Cancer & Oncology Source Type: podcasts
Targeting HER2, BRAF, KRAS, MET
The 20th Annual Perspectives in Thoracic Oncology, held in New York, NY from November 21-22, 2015 provided thoracic oncology clinicians and researchers with the latest information on the complex biolo...
Author: imedex
Added: 02/08/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 8, 2016 Category: Cancer & Oncology Source Type: podcasts
ToGA trial and how it changed the management of HER2+ gastric carcinoma ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: How did the ToGA trial changed the management of HER2+ gastric carcinoma
Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts
@OncEd Presents Dr. Wendie Den Brok - Survival of Metastatic HR Positive/HER2 Negative, Triple Negative and HER2 Positive Breast Cancer - Best of Oncology West 2015
Author: oncologyeducation
Added: 12/02/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 2, 2015 Category: Cancer & Oncology Source Type: podcasts
